Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists

被引:27
作者
Garabet, Lamya [1 ,2 ,3 ]
Ghanima, Waleed [3 ,4 ,5 ]
Rangberg, Anbjorg [2 ]
Teruel-Montoya, Raul [6 ,7 ]
Martinez, Constantino [6 ]
Lozano, Maria Luisa [6 ,7 ]
Nystrand, Camilla F. [2 ]
Bussel, James B. [8 ]
Sandset, Per Morten [3 ,9 ,10 ]
Jonassen, Christine M. [2 ,11 ]
机构
[1] Akershus Univ Hosp, Multidisciplinary Lab Med & Med Biochem, Lorenskog, Norway
[2] Ostfold Hosp Trust, Ctr Lab Med, Gralum, Norway
[3] Univ Oslo, Inst Clin Med, Oslo, Norway
[4] Ostfold Hosp Trust, Dept Res, Gralum, Norway
[5] Ostfold Hosp Trust, Dept Med, Gralum, Norway
[6] Univ Murcia, Serv Hematol & Oncol Med, IMIB Arrixaca, Hosp Univ Morales Meseguer,Ctr Reg Hemodonac, Murcia, Spain
[7] Inst Salud Carlos III ISCIII, Grp Invest Ctr Invest Biomed Red Enfermedades Rar, Madrid, Spain
[8] New York Presbyterian Hosp, Dept Pediat, Div Hematol, Weill Cornell Med, New York, NY USA
[9] Oslo Univ Hosp, Dept Haematol, Oslo, Norway
[10] Oslo Univ Hosp, Res Inst Internal Med, Oslo, Norway
[11] Norwegian Univ Life Sci, Fac Chem Biotechnol & Food Sci, As, Norway
关键词
ITP; microRNAs; TPO-RAs; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; DROPLET DIGITAL PCR; DOWN-REGULATION; EXPRESSION; BIOMARKERS; CELLS; QUANTIFICATION; APOPTOSIS; EFFICACY; PURPURA;
D O I
10.1080/09537104.2019.1585527
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
MicroRNAs (miRNAs) are small non-coding RNAs involved in the regulation of gene expression. Dysregulated expression of several miRNAs has been found in primary immune thrombocytopenia (ITP) suggesting that miRNAs are likely involved in the pathogenesis of ITP. We aimed to explore the differential expression of miRNAs in patients with ITP before and after starting treatment with thrombopoietin-receptor agonists (TPO-RAs) to clarify their roles in the pathophysiology of ITP, and as potential diagnostic and prognostic markers of this disorder. We performed a profiling study where 179 miRNAs were analyzed in eight ITP patients before and during treatment with TPO-RAs and in eight controls using miRNA PCR panel; 81 miRNAs were differentially expressed in ITP patients compared to controls, and 14 miRNAs showed significant changes during TPO-RA-treatment. Ten miRNAs were selected for validation that was performed in 23 patients and 22 controls using droplet digital PCR. Three miRNAs were found to be differentially expressed in ITP patients before TPO-RA-treatment compared to controls: miR-199a-5p was down-regulated (p = 0.0001), miR-33a-5p (p = 0.0002) and miR-195-5p (p = 0.035) were up-regulated. Treatment with TPO-RAs resulted in changes in six miRNAs including miR-199a-5p (p = 0.001), miR-33a-5p (p = 0.003), miR-382-5p (p = 0.004), miR-92b-3p (p = 0.005), miR-26a-5p (p = 0.008) and miR-221-3p (p = 0.023); while miR-195-5p remained unchanged and significantly higher than in controls, despite the increase in the platelet count, which may indicate its possible role in the pathophysiology of ITP. Regression analysis revealed that pre-treatment levels of miR-199a-5p and miR-221-3p could help to predict platelet response to TPO-RA-treatment. ROC curve analysis showed that the combination of miR-199a-5p and miR-33a-5p could distinguish patients with ITP from controls with AUC of 0.93. This study identifies a number of differentially expressed miRNAs in ITP patients before and after initiation of TPO-RAs with potential roles in the pathophysiology, as well as with a possible utility as diagnostic and prognostic biomarkers. These interesting findings deserve further exploration and validation in future studies.
引用
收藏
页码:198 / 205
页数:8
相关论文
共 41 条
[1]  
Bai R, 2015, EUR REV MED PHARMACO, V19, P545
[2]   MicroRNAs: Target Recognition and Regulatory Functions [J].
Bartel, David P. .
CELL, 2009, 136 (02) :215-233
[3]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[4]   Plasma microRNA profiling of pediatric patients with immune thrombocytopenic purpura [J].
Bay, Ali ;
Coskun, Enes ;
Oztuzcu, Serdar ;
Ergun, Sercan ;
Yilmaz, Fatih ;
Aktekin, Elif .
BLOOD COAGULATION & FIBRINOLYSIS, 2014, 25 (04) :379-383
[5]   Profiling of miRNA expression in immune thrombocytopenia patients before and after Qishunbaolier (QSBLE) treatment [J].
Burenbatu ;
Borjigin, Mandula ;
Eerdunduleng ;
Huo, Wenyan ;
Gong, Cuiqin ;
Hasengaowa ;
Zhang, Guiping ;
Longmei ;
Li, Ming ;
Zhang, Xuemei ;
Sun, Xiaohui ;
Yang, Jie ;
Wang, Shuanglian ;
Narisu, Narisu ;
Liu, Yangjian ;
Bai, Haihua .
BIOMEDICINE & PHARMACOTHERAPY, 2015, 75 :196-204
[6]  
Bussel JB, 2010, BLOOD, V116
[7]   A comparison between quantitative PCR and droplet digital PCR technologies for circulating microRNA quantification in human lung cancer [J].
Campomenosi, Paola ;
Gini, Elisabetta ;
Noonan, Douglas M. ;
Poli, Albino ;
D'Antona, Paola ;
Rotolo, Nicola ;
Dominioni, Lorenzo ;
Imperatori, Andrea .
BMC BIOTECHNOLOGY, 2016, 16
[8]   Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases [J].
Chen, Xi ;
Ba, Yi ;
Ma, Lijia ;
Cai, Xing ;
Yin, Yuan ;
Wang, Kehui ;
Guo, Jigang ;
Zhang, Yujing ;
Chen, Jiangning ;
Guo, Xing ;
Li, Qibin ;
Li, Xiaoying ;
Wang, Wenjing ;
Zhang, Yan ;
Wang, Jin ;
Jiang, Xueyuan ;
Xiang, Yang ;
Xu, Chen ;
Zheng, Pingping ;
Zhang, Juanbin ;
Li, Ruiqiang ;
Zhang, Hongjie ;
Shang, Xiaobin ;
Gong, Ting ;
Ning, Guang ;
Wang, Jun ;
Zen, Ke ;
Zhang, Junfeng ;
Zhang, Chen-Yu .
CELL RESEARCH, 2008, 18 (10) :997-1006
[9]  
Dai L, 2015, INT J CLIN EXP PATHO, V8, P4735
[10]   How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment [J].
Ghanima, Waleed ;
Godeau, Bertrand ;
Cines, Douglas B. ;
Bussel, James B. .
BLOOD, 2012, 120 (05) :960-969